Sight Sciences, INC Form 4 insider transactions

Sight Sciences, Inc. Director Catherine Mazzacco was granted 30,952 Restricted Stock Units (RSUs) valued at approximately $130,000, aligning her interests with shareholders.

Brenda Jane Larsen-Becker, a Director at Sight Sciences, Inc., was granted 30,952 Restricted Stock Units valued at approximately $130,000 as part of the company's Non-Employee Director Compensation Program.

Sight Sciences, Inc. Director Erica J. Rogers was granted 30,952 restricted stock units (RSUs) on June 5, 2025, as part of the company's non-employee director compensation program.

Sight Sciences, Inc. Director Tamara Fountain, M.D., was granted 30,952 restricted stock units (RSUs) valued at approximately $130,000 as part of the company's Non-Employee Director Compensation Program.

Sight Sciences, Inc. Director Donald Zurbay was granted 30,952 restricted stock units (RSUs) valued at approximately $130,000 as part of the company's non-employee director compensation program.

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc. (SGHT), has increased his direct beneficial ownership through multiple stock purchases totaling 90,525 shares and a grant of 30,952 restricted stock units (RSUs) in early June 2025.

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc., has significantly increased his direct beneficial ownership by purchasing 98,782 shares of common stock across three transactions in late May and early June 2025.

Staffan Encrantz, a Director and 10% owner of Sight Sciences, Inc., has significantly increased his direct beneficial ownership through multiple open market purchases of common stock totaling 128,189 shares over three days in late May 2025.

Manohar K. Raheja, EVP of Research & Development at Sight Sciences, acquired 12,767 shares of common stock through the company's Employee Stock Purchase Plan at a price of $3.018 per share on May 16, 2025.

Alison Bauerlein, CFO of Sight Sciences, sold 13,066 shares of common stock on May 19, 2025, to cover tax liabilities related to vesting restricted stock units.

Matthew Link, Chief Commercial Officer of Sight Sciences, acquired 6,631 shares of common stock through the company's Employee Stock Purchase Plan.

Director Gerhard F. Burbach of Sight Sciences, Inc. received a grant of restricted stock units (RSUs) on May 12, 2025, under the company's Non-Employee Director Compensation Program.

Jeremy B. Hayden, Chief Legal Officer of Sight Sciences, Inc., sold 9,395 shares of common stock on April 2, 2025, to cover tax liabilities related to vesting restricted stock units.

Sight Sciences CEO Paul Badawi sold 24,174 shares of common stock on April 1, 2025, to cover tax liabilities related to the vesting of restricted stock units.

Matthew Link, Chief Commercial Officer of Sight Sciences, sold 5,042 shares of common stock on April 2, 2025, to cover tax liabilities related to vesting restricted stock units.

David Badawi, Chief Technology Officer of Sight Sciences, sold 5,980 shares of common stock on April 1, 2025, to cover tax liabilities related to vesting restricted stock units.

Alison Bauerlein, CFO of Sight Sciences, sold 19,397 shares of common stock on April 2, 2025, to cover tax liabilities related to vesting restricted stock units.

Alison Bauerlein, CFO of Sight Sciences, Inc., reports receiving a grant of restricted stock units (RSUs) under the company's 2021 Incentive Award Plan.

Jeremy Hayden, Chief Legal Officer of Sight Sciences, Inc., was granted 139,785 restricted stock units (RSUs) on March 11, 2025, under the company's 2021 Incentive Award Plan.

Sight Sciences CEO Paul Badawi was granted 358,423 restricted stock units (RSUs) under the company's 2021 Incentive Award Plan.

David Badawi, Chief Technology Officer of Sight Sciences, Inc., reports the acquisition of 98,566 shares of common stock through a restricted stock unit (RSU) grant.

Matthew Link, Chief Commercial Officer of Sight Sciences, was granted 172,043 restricted stock units (RSUs) on March 11, 2025, vesting quarterly over four years.

Manohar K. Raheja, EVP of Research & Development at Sight Sciences, reports acquisition and disposal of common stock and grant of restricted stock units.

Staffan Encrantz, a director and 10% owner of Sight Sciences, Inc., has increased his stake in the company through a series of open market purchases.

David Badawi, Chief Technology Officer of Sight Sciences, sold 5,423 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences CEO, Paul Badawi, sold 24,819 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 6,922 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences' Chief Legal Officer, Jeremy B. Hayden, sold 1,810 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Sight Sciences CEO Paul Badawi sold 12,047 shares of common stock to cover tax liabilities related to vesting restricted stock units.

David Badawi, Chief Technology Officer of Sight Sciences, sold 3,829 shares of common stock to cover tax liabilities related to vesting restricted stock units.